Literature DB >> 2565725

Prolonged Q-T interval following astemizole overdose.

R O Bishop1, P L Gaudry.   

Abstract

Astemizole overdose has been reported to cause torsades-de-pointes and in the present case it caused prolongation of the Q-T interval. Astemizole overdoses should be managed in a similar way to overdose with other cardiotoxic drugs.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2565725      PMCID： PMC1285561          DOI： 10.1136/emj.6.1.63

Source DB:  PubMed          Journal:  Arch Emerg Med        ISSN： 0264-4924


  4 in total

1.  A report of overdose with astemizole.

Authors:  J C Kingswood; P A Routledge; J H Lazarus
Journal:  Hum Toxicol       Date:  1986-01

2.  Torsades de pointes associated with drugs and toxins: recognition and management.

Authors:  H G Stratmann; H L Kennedy
Journal:  Am Heart J       Date:  1987-06       Impact factor: 4.749

3.  ECG studies with astemizole.

Authors:  T M Craft; G Vanden Bussche; J De Cree; J V Griffiths
Journal:  Hum Toxicol       Date:  1987-11

4.  Torsade de pointes after astemizole overdose.

Authors:  T M Craft
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-08
  4 in total
  7 in total

1.  Rate-dependent blockade of a potassium current in human atrium by the antihistamine loratadine.

Authors:  W J Crumb
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

2.  Public health problems and the rapid estimation of the size of the population at risk. Torsades de pointes and the use of terfenadine and astemizole in The Netherlands.

Authors:  R M Herings; B H Stricker; H G Leufkens; A Bakker; F Sturmans; J Urquhart
Journal:  Pharm World Sci       Date:  1993-10-15

Review 3.  H1-receptor antagonists. Comparative tolerability and safety.

Authors:  F E Simons
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

Review 4.  Safety of antihistamines in children.

Authors:  A P Ten Eick; J L Blumer; M D Reed
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

5.  The combination astemizole-gefitinib as a potential therapy for human lung cancer.

Authors:  María de Guadalupe Chávez-López; Violeta Zúñiga-García; Elisabeth Hernández-Gallegos; Eunice Vera; Carmen Alexandra Chasiquiza-Anchatuña; Marco Viteri-Yánez; Janet Sanchez-Ramos; Efraín Garrido; Javier Camacho
Journal:  Onco Targets Ther       Date:  2017-12-06       Impact factor: 4.147

Review 6.  Toward a broader view of mechanisms of drug cardiotoxicity.

Authors:  Polina Mamoshina; Blanca Rodriguez; Alfonso Bueno-Orovio
Journal:  Cell Rep Med       Date:  2021-03-16

Review 7.  Cardiovascular safety of antihistamines.

Authors:  Anna Olasińska-Wiśniewska; Jerzy Olasiński; Stefan Grajek
Journal:  Postepy Dermatol Alergol       Date:  2014-06-13       Impact factor: 1.837
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.